Akebia Therapeutics, Inc. announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston from April 10-13, 2025. The company will display ...

If you've got the perfect spot to grow a beautiful vining plant, it's important to know which ones support the ecosystem and those that can cause harm.

Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

Akebia Therapeutics shares were down 20% to $2.27 after the company priced its underwritten public offering of 25 million shares at $2 a share. All shares are being offered by Akebia. The proceeds ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by ...

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. Shares of JOYY Inc. YY fell sharply in today's pre-market trading following weak quarterly ...

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Akebia Therapeutics, Inc. before investing. In this article, we go over a few key ...

CAMBRIDGE, Mass. - Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focusing on kidney disease treatments with a current market capitalization of $673 million, announced today the ...